1 / 7

DELEGATION

PHARMACOVILANCE ACTIVITIES IN CÔTE D’IVOIRE. DELEGATION. Dr Yao (WHO-CI) Dr N’Guessan-Irié (DPM). PRESENTETION OF THE COUNTRY. Côte d’Ivoire is a french speaking country in west Africa Area: 322.462 km 2 Population: about 20 millions (1998)

sadie
Télécharger la présentation

DELEGATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PHARMACOVILANCE ACTIVITIES IN CÔTE D’IVOIRE DELEGATION Dr Yao (WHO-CI) Dr N’Guessan-Irié (DPM)

  2. PRESENTETION OF THE COUNTRY • Côte d’Ivoire is a french speaking country in west Africa • Area: 322.462 km2 • Population: about 20 millions (1998) • National level of HIV: 4.7% (higher in some areas) • War in 2002 • PNPEC = program in charge of people living with HIV • SCMS, PEPFAR, CARE, EGPAF, Clinton Foundation…(ARV products suppliers)

  3. INTRODUCTION • No National Centre of Pharmacovigilance • Pharmacovigilance supported by DPM (Direction de la Pharmacie et du Médicament) • Project of a Pharmacovigilance Centre creation • Project of Pharmacovigilance of ARVs in PNPEC

  4. CURRENT ACTIVITIES of DPM • Reception of reports from AFSSAPS and Pharmaceutical Plants • Diffusion of informations to health practitioners • Information of the Ministry in charge of health for decisions

  5. PROJECT FOR THE CENTRE • Identification of products adverse reactions in hospitals, chemist’ shops, program of specific diseases (HIV, TB, leprosy…) • Studies of the different reports at the National Centre • Answers of the Centre to those who notify • Collaboration with international systems (UPSALA, AFSSAPS…) • Form a database for further needs

  6. CONCLUSION • At present no Pharmacovigilance specific for ARV medicines • The present workshop will contribute to implement pharmacovigilance of ARV medicines in our country

  7. THANKYOU FOR PAYING ATTENTION

More Related